Jennison Associates
DCPH

Jennison Associates’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Jennison Associates’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-72,074
Closed -$2.97M – 711
2020
Q1 		$2.97M Buy
72,074
+514
+0.7% +$28.5K ﹤0.01% 429
2019
Q4 		$4.45M Buy
+71,560
New +$3.4M ﹤0.01% 441

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Jennison Associates's DCPH Position: Q2 2020 in Review

Jennison Associates sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2020, closing a stake of 72,074 shares — an estimated $2.97M sold.

Jennison Associates first reported a position in DCPH in Q4 2019 and held it in 2 quarters. The position peaked at $4.45M in Q4 2019. 168 funds tracked by Wall St. Rank hold DCPH as of Q2 2020.

  • Jennison Associates reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Jennison Associates sold 72,074 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $2.97M.
  • Jennison Associates first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Jennison Associates's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $4.45M in Q4 2019.
  • 168 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Jennison Associates's 13F filing for Q2 2020, filed 6 Aug 2020.